
  
    
      
        Introduction_NNP
        The_DT term_NN acute_JJ renal_JJ failure_NN (_( ARF_NNP )_) has_VBZ been_VBN used_VBN to_TO
        encompass_VB a_DT wide_JJ variety_NN of_IN clinical_JJ disorders_NNS ranging_VBG from_IN
        glomerulonephritis_NNS to_TO prerenal_NN azotemia_NN ._. It_PRP is_VBZ generally_RB
        defined_VBN as_IN a_DT rapid_JJ decline_NN (_( within_IN hours_NNS to_TO weeks_NNS )_) in_IN
        glomerular_NN filtration_NN rate_NN (_( GFR_NNP )_) and_CC retention_NN of_IN
        nitrogenous_JJ waste_NN products_NNS ._. Each_DT underlying_VBG disorder_NN has_VBZ
        its_PRP$ own_JJ unique_JJ pathophysiology_NN and_CC separate_JJ set_NN of_IN
        etiologies_NNS ._. Furthermore_RB ,_, many_JJ of_IN these_DT clinical_JJ syndromes_NNS
        have_VBP specific_JJ treatments_NNS ._. Accordingly_RB ,_, it_PRP is_VBZ not_RB possible_JJ
        to_TO consider_VB the_DT issue_NN of_IN whether_IN diuretics_NNS or_CC dopamine_NN are_VBP
        useful_JJ in_IN ARF_NNP without_IN first_JJ considering_VBG the_DT differences_NNS
        between_IN these_DT individual_JJ disorders_NNS ._. Moreover_RB ,_, data_NNS drawn_VBN
        from_IN animal_NN experiments_NNS ,_, where_WRB compounds_NNS such_JJ as_IN uranyl_NN
        nitrate_NN or_CC glycerol_NN were_VBD used_VBN to_TO induce_VB ARF_NNP ,_, must_MD be_VB
        interpreted_VBN with_IN caution_NN [_NN 1_CD ]_NN ._. Still_RB ,_, much_JJ of_IN our_PRP$
        understanding_NN of_IN these_DT disorders_NNS ,_, and_CC the_DT effects_NNS of_IN
        various_JJ treatments_NNS ,_, comes_VBZ from_IN these_DT models_NNS ._. In_IN general_JJ ,_,
        diuretics_NNS and_CC /_NN or_CC dopamine_NN are_VBP usually_RB considered_VBN for_IN the_DT
        prevention_NN or_CC treatment_NN of_IN acute_JJ tubular_JJ necrosis_NNS (_( ATN_NNP )_) ._.
        The_DT basic_JJ rationale_NN is_VBZ that_IN ischemic_JJ ATN_NNP should_MD be_VB improved_VBN
        by_IN increasing_VBG renal_JJ blood_NN flow_NN and_CC that_IN tubular_JJ obstruction_NN
        should_MD be_VB decreased_VBN by_IN maintaining_VBG urine_NN flow_NN ._.
        The_DT use_NN of_IN diuretics_NNS to_TO prevent_VB or_CC even_RB '_POS treat_NN '_POS renal_JJ
        dysfunction_NN has_VBZ become_VBN a_DT widely_RB accepted_VBN clinical_JJ practice_NN ._.
        Indeed_RB ,_, management_NN protocols_NNS for_IN some_DT routine_JJ patients_NNS
        often_RB include_VBP orders_NNS for_IN furosemide_NN when_WRB urine_NN output_NN falls_VBZ
        below_IN some_DT cutoff_NN value_NN ._. Some_DT protocols_NNS even_RB utilize_VB
        socalled_JJ '_POS renal-dose_JJ '_POS dopamine_NN in_IN these_DT circumstances_NNS ._. It_PRP
        is_VBZ therefore_RB necessary_JJ to_TO review_VB the_DT evidence_NN in_IN support_NN of_IN
        such_JJ practices_NNS ._. Given_VBN the_DT broad_JJ range_NN of_IN conditions_NNS
        predisposing_VBG to_TO ARF_NNP and_CC the_DT multiple_JJ comorbidities_NNS of_IN
        critically_RB ill_JJ patients_NNS ,_, a_DT systematic_JJ review_NN addressing_VBG the_DT
        effect_NN of_IN different_JJ treatments_NNS must_MD be_VB interpreted_VBN in_IN light_NN
        of_IN these_DT clinical_JJ features_NNS ._. Therefore_RB ,_, the_DT purpose_NN of_IN this_DT
        review_NN was_VBD to_TO evaluate_VB the_DT impact_NN of_IN diuretics_NNS and_CC dopamine_NN
        for_IN both_DT the_DT prevention_NN and_CC treatment_NN of_IN renal_JJ dysfunction_NN
        in_IN the_DT acute_JJ care_NN setting_NN ._.
      
      
        Methods_NNP
        
          Search_NNP strategy_NN
          A_DT MEDLINE_NNP search_NN was_VBD conducted_VBN using_VBG databases_NNS from_IN
          1966_CD to_TO May_NNP 1997_CD ._. Articles_NNPS dealing_VBG with_IN kidney_NN (_( drug_NN
          effects_NNS )_) and_CC diuretics_NNS or_CC dopamine_NN were_VBD searched_VBD ._. This_DT
          pool_NN of_IN articles_NNS was_VBD then_RB limited_VBN to_TO English_NNP language_NN
          clinical_JJ trials_NNS or_CC meta-analyses_JJ of_IN human_JJ studies_NNS ._.
          Bibliographies_NNP of_IN review_NN articles_NNS on_IN these_DT topics_NNS were_VBD
          also_RB searched_VBD by_IN hand_NN for_IN additional_JJ studies_NNS meeting_VBG the_DT
          above_JJ criteria_NNS ._. This_DT group_NN of_IN articles_NNS was_VBD then_RB screened_VBD
          by_IN the_DT author_NN for_IN studies_NNS addressing_VBG the_DT use_NN of_IN diuretics_NNS
          or_CC dopamine_NN in_IN the_DT prevention_NN and_CC /_NN or_CC treatment_NN of_IN
          ARF_NNP ._.
        
        
          Inclusion_NNP and_CC exclusion_NN criteria_NNS
          For_IN the_DT purpose_NN of_IN this_DT review_NN only_RB loop_NN diuretics_NNS ,_,
          mannitol_NN and_CC dopamine_NN were_VBD included_VBN ._. Loop_NNP diuretics_NNS
          included_VBD the_DT agents_NNS furosemide_NN ,_, bumetanide_NN and_CC torsemide_NN ._.
          These_DT agents_NNS have_VBP become_VBN the_DT most_RBS widely_RB used_VBN for_IN the_DT
          indications_NNS considered_VBN in_IN this_DT review_NN ._. Although_IN
          ethacrynic_JJ acid_NN is_VBZ also_RB a_DT loop_NN diuretic_JJ ,_, it_PRP was_VBD excluded_VBN
          because_IN it_PRP is_VBZ not_RB commonly_RB used_VBN in_IN clinical_JJ practice_NN ._.
          Additionally_RB ,_, other_JJ diuretic_JJ agents_NNS such_JJ as_IN thiazides_NNS
          were_VBD excluded_VBN ._. Similarly_RB ,_, this_DT review_NN will_MD not_RB discuss_VB
          any_DT of_IN the_DT yet_RB experimental_JJ agents_NNS such_JJ as_IN atrial_NN
          natriuretic_JJ factor_NN ._. The_DT primary_JJ analysis_NN included_VBD only_RB
          studies_VBZ that_WDT involved_VBD humans_NNS and_CC were_VBD published_VBN in_IN
          English_NNP ._.
        
        
          Critical_JJ appraisal_NN methods_NNS
          Individual_JJ studies_NNS were_VBD graded_JJ by_IN levels_NNS according_VBG to_TO
          the_DT criteria_NNS in_IN Table_NNP 1_CD ,_, adapted_VBN from_IN Cook_NNP 
          et_CC al_NN [_NN 2_CD ]_NN ._. When_WRB multiple_JJ studies_NNS
          were_VBD available_JJ ,_, the_DT highest_JJS level_NN study_NN was_VBD used_VBN ._.
          Clinical_NNP trials_NNS of_IN the_DT effectiveness_NN of_IN diuretics_NNS or_CC
          dopamine_NN were_VBD judged_VBN to_TO be_VB effective_JJ only_RB if_IN the_DT outcome_NN
          measures_NNS were_VBD of_IN clinical_JJ significance_NN (_( eg_NN mortality_NN ,_,
          need_NN for_IN hemodialysis_NNS )_) or_CC in_IN terms_NNS of_IN biochemical_JJ
          evidence_NN of_IN organ_NN function_NN (_( serum_NN creatinine_NN or_CC
          creatinine_NN clearance_NN )_) following_VBG the_DT maneuver_NN ._. Surrogate_NNP
          markers_NNS such_JJ as_IN urine_NN output_NN or_CC renal_JJ blood_NN flow_NN were_VBD not_RB
          considered_VBN as_IN evidence_NN of_IN effectiveness_NN ._. Furthermore_RB ,_,
          trials_NNS of_IN dopamine_NN were_VBD not_RB considered_VBN controlled_VBN unless_IN
          confounding_VBG variables_NNS such_JJ as_IN blood_NN pressure_NN and_CC cardiac_JJ
          output_NN were_VBD reported_VBN ._. Similarly_RB ,_, for_IN both_DT diuretics_NNS and_CC
          dopamine_NN ,_, the_DT volume_NN status_NN of_IN the_DT control_NN and_CC treatment_NN
          groups_NNS must_MD have_VB been_VBN similar_JJ ._.
        
      
      
        Results_NNS
        
          Radiocontrastinduced_NNP ATN_NNP
          Radiocontrast-induced_NNP ATN_NNP is_VBZ rare_JJ in_IN patients_NNS without_IN
          underlying_VBG renal_JJ ,_, cardiac_JJ or_CC hepatic_JJ dysfunction_NN and_CC
          occurs_VBZ most_RBS commonly_RB in_IN patients_NNS with_IN diabetic_JJ
          nephropathy_NN [_NN 43_CD ]_NN ._. In_IN this_DT group_NN the_DT incidence_NN approaches_NNS
          50_CD %_NN ,_, depending_VBG on_IN the_DT degree_NN of_IN baseline_NN renal_JJ function_NN
          and_CC the_DT use_NN of_IN ionic_JJ 
          vs_NNS nonionic_JJ contrast_NN media_NNS [_NN 44_CD ]_NN ._.
          Several_JJ forms_NNS of_IN therapy_NN have_VBP been_VBN proposed_VBN to_TO prevent_VB or_CC
          treat_VB radiocontrast-induced_JJ ATN_NNP ,_, including_VBG saline_NN ,_,
          furosemide_NN ,_, mannitol_NN ,_, calcium_NN channel_NN blockers_NNS ,_, dopamine_NN ,_,
          atrial_NN natriuretic_JJ peptide_NN and_CC theophylline_NN [_NN 44_CD ]_NN ._. There_EX
          are_VBP no_DT placebo_NN controlled_VBD trials_NNS testing_VBG the_DT
          effectiveness_NN of_IN any_DT of_IN these_DT therapies_NNS ._. Virtually_RB all_DT
          studies_NNS have_VBP used_VBN hydration_NN (_( usually_RB with_IN 0_CD ._. 45_CD %_NN saline_NN )_)
          in_IN addition_NN to_TO the_DT agent_NN being_VBG tested_VBN and_CC most_JJS authors_NNS
          recommend_VBP its_PRP$ use_NN ._. However_RB ,_, even_RB then_RB ,_, little_RB comparative_JJ
          data_NNS exist_VBP for_IN these_DT potential_JJ treatments_NNS ._. One_CD exception_NN
          is_VBZ the_DT study_NN by_IN Solomon_NNP 
          et_CC al_NN [_NN 3_CD ]_NN which_WDT compared_VBD the_DT
          effects_NNS of_IN furosemide_NN plus_CC saline_NN ,_, mannitol_NN plus_CC saline_NN
          and_CC saline_NN alone_RB ;_: again_RB ,_, 0_CD ._. 45_CD %_NN saline_NN was_VBD used_VBN ._. This_DT
          randomized_JJ trial_NN of_IN 78_CD `_`` high-risk_JJ '_'' patients_NNS found_VBD that_IN
          both_DT diuretic_JJ regimens_NNS were_VBD less_RBR effective_JJ in_IN preventing_VBG
          ATN_NNP than_IN saline_NN alone_RB (_( relative_JJ risk_NN of_IN ATN_NNP using_VBG
          mannitol_NN 2_CD ._. 5_CD or_CC furosemide_NN 3_CD ._. 6_CD 
          vs_NNS saline_NN alone_RB ;_: 
          P_NN =_SYM 0_CD ._. 02_CD )_) ._. Another_DT study_NN ,_, by_IN
          Weinstein_NNP 
          et_CC al_NN ,_, found_VBD that_IN renal_JJ function_NN
          significantly_RB deteriorated_VBD in_IN patients_NNS pretreated_JJ with_IN
          furosemide_NN [_NN 4_CD ]_NN ._.
          As_IN shown_VBN in_IN Table_NNP 1_CD ,_, to_TO date_NN only_RB two_CD clinical_JJ trials_NNS
          have_VBP been_VBN published_VBN using_VBG dopamine_NN to_TO prevent_VB
          radiocontrastinduced_JJ ATN_NNP ._. Hall_NNP 
          et_CC al_NN [_NN 28_CD ]_NN studied_VBD the_DT effects_NNS of_IN
          dopamine_NN infusion_NN on_IN serum_NN creatinine_NN assessed_VBN at_IN day_NN 3_CD
          after_IN radiocontrast_NN administration_NN in_IN patients_NNS with_IN
          baseline_NN serum_NN creatinine_NN levels_NNS of_IN >_NN 2_CD ._. 0_CD mg_NN /_NN dl_NN ._. This_DT
          level_JJ III_NNP study_NN did_VBD show_NN an_DT improvement_NN in_IN serum_NN
          creatinine_NN with_IN dopamine_NN compared_VBN to_TO a_DT control_NN group_NN
          which_WDT received_VBD mannitol_NN ._. However_RB ,_, given_VBN the_DT evidence_NN that_DT
          mannitol_NN may_MD actually_RB be_VB harmful_JJ in_IN this_DT setting_VBG [_NN 3_CD ]_NN ,_,
          this_DT was_VBD probably_RB not_RB the_DT appropriate_JJ control_NN group_NN ._. In_IN
          the_DT only_RB other_JJ controlled_VBN trial_NN ,_, Weisberg_NNP 
          et_CC al_NN [_NN 24_CD ]_NN found_VBD no_DT difference_NN in_IN
          the_DT incidence_NN of_IN ATN_NNP with_IN or_CC without_IN dopamine_NN (_( 30_CD -_: 40_CD %_NN )_) in_IN
          a_DT small_JJ series_NN of_IN patients_NNS (_( 
          n_NN =_SYM 30_CD )_) ._. Thus_RB ,_, for_IN this_DT indication_NN
          we_PRP can_MD safely_RB conclude_VB that_IN diuretics_NNS and_CC dopamine_NN are_VBP
          clearly_RB not_RB helpful_JJ and_CC may_MD even_RB be_VB harmful_JJ ,_, while_IN volume_NN
          expansion_NN with_IN 0_CD ._. 45_CD %_NN saline_NN is_VBZ unproven_JJ but_CC potentially_RB
          beneficial_JJ ._.
        
        
          Prevention_NNP of_IN ischemic_JJ ATN_NNP
          Of_IN the_DT five_CD studies_NNS listed_VBN in_IN Table_NNP 1_CD ,_, only_RB one_CD trial_NN
          used_VBD loop_NN diuretics_NNS ._. Hager_NNP 
          et_CC al_NN [_NN 8_CD ]_NN randomized_JJ 121_CD patients_NNS
          to_TO receive_VB either_CC furosemide_NN (_( 1_CD mg_NN /_NN h_NN )_) or_CC placebo_NN starting_VBG
          immediately_RB after_IN major_JJ thoraco-abdominal_JJ or_CC vascular_NN
          surgery_NN and_CC continuing_VBG throughout_IN the_DT intensive_JJ care_NN unit_NN
          (_( ICU_NNP )_) stay_VB ._. The_DT authors_NNS measured_VBD creatinine_NN clearance_NN and_CC
          found_VBD no_DT difference_NN between_IN furosemide_NN and_CC placebo_NN ._.
          Unfortunately_RB ,_, the_DT study_NN was_VBD unable_JJ to_TO address_VB the_DT use_NN of_IN
          loop_NN diuretics_NNS given_VBN during_IN the_DT procedure_NN ._.
          The_DT facts_NNS are_VBP even_RB less_RBR clear_JJ regarding_VBG mannitol_NN in_IN
          vascular_NN surgery_NN ._. The_DT only_RB controlled_VBN study_NN available_JJ is_VBZ
          by_IN Beall_NNP 
          et_CC al_NN from_IN 1963_CD [_NN 5_CD ]_NN ._. This_DT study_NN
          compared_VBD the_DT outcomes_NNS of_IN 30_CD patients_NNS who_WP underwent_VBD
          elective_JJ abdominal_NN aortic_JJ aneurysm_NN repair_NN ._. Patients_NNS were_VBD
          randomized_JJ to_TO receive_VB either_CC no_DT pre-operative_JJ fluid_NN ,_, iv_NN
          hydration_NN only_RB or_CC iv_NN hydration_NN plus_CC mannitol_NN as_IN required_VBN
          to_TO keep_VB urine_NN output_NN >_NN 60_CD ml_NN /_NN min_NN ._. There_EX was_VBD no_DT change_NN
          in_IN renal_JJ function_NN or_CC postoperative_JJ urine_NN output_NN between_IN
          the_DT latter_JJ two_CD groups_NNS ._. Although_IN this_DT negative_JJ study_NN was_VBD
          certainly_RB underpowered_JJ ,_, it_PRP remains_VBZ the_DT only_RB controlled_VBN
          trial_NN of_IN mannitol_NN in_IN vascular_NN surgery_NN to_TO date_NN ._. The_DT
          following_VBG year_NN ,_, Powers_NNP 
          et_CC al_NN reported_VBD the_DT outcomes_NNS of_IN 104_CD
          patients_NNS treated_VBN with_IN mannitol_NN [_NN 6_CD ]_NN ._. This_DT uncontrolled_JJ
          study_NN reported_VBD that_IN all_DT patients_NNS had_VBD an_DT increase_NN in_IN urine_NN
          output_NN and_CC none_NN developed_VBD ATN_NNP ._. No_DT recent_JJ studies_NNS have_VBP
          been_VBN carried_VBN out_IN to_TO address_VB this_DT issue_NN and_CC it_PRP is_VBZ unlikely_JJ
          that_IN any_DT will_MD ._. In_IN other_JJ types_NNS of_IN surgery_NN ,_, such_JJ as_IN
          coronary_JJ artery_NN bypass_NN [_NN 9_CD ]_NN or_CC biliary_JJ surgery_NN [_NN 10_CD ]_NN ,_,
          small_JJ studies_NNS have_VBP also_RB been_VBN unable_JJ to_TO demonstrate_VB a_DT
          benefit_NN associated_VBN with_IN mannitol_NN ._. Given_VBN these_DT
          considerations_NNS ,_, and_CC in_IN the_DT absence_NN of_IN clinical_JJ data_NNS ,_,
          diuretics_NNS cannot_NN be_VB recommended_VBN to_TO prevent_VB ATN_NNP ._.
          Thirty_NNP clinical_JJ studies_NNS of_IN dopamine_NN have_VBP been_VBN
          published_VBN to_TO date_NN ,_, both_DT for_IN prevention_NN of_IN ATN_NNP and_CC
          treatment_NN of_IN early_JJ ATN_NNP (_( including_VBG radiocontrast-induced_JJ
          ATN_NNP )_) ._. However_RB ,_, only_RB 20_CD of_IN these_DT used_VBN outcomes_NNS other_JJ than_IN
          surrogate_JJ markers_NNS (_( eg_NN urine_NN output_NN ,_, renal_JJ blood_NN flow_NN )_) ,_,
          and_CC only_RB three_CD were_VBD positive_JJ ._. These_DT included_VBD the_DT study_NN by_IN
          Hall_NNP 
          et_CC al_NN [_NN 28_CD ]_NN ,_, cited_VBD above_IN ,_, and_CC two_CD
          others_NNS which_WDT were_VBD both_DT methodologically_RB inferior_JJ ,_, one_CD
          level_NN IV_NNP and_CC one_CD level_NN V_NNP ._. Polson_NNP 
          et_CC al_NN [_NN 38_CD ]_NN found_VBD a_DT significant_JJ
          difference_NN in_IN creatinine_NN clearance_NN and_CC a_DT decrease_NN in_IN ARF_NNP
          in_IN liver_NN transplant_NN patients_NNS treated_VBN with_IN 2_CD μg_NN /_NN kg_NN /_NN min_NN
          dopamine_NN ._. The_DT findings_NNS of_IN this_DT level_JJ IV_NNP study_NN were_VBD not_RB
          supported_VBN by_IN a_DT level_JJ II_NNP study_NN from_IN Swygert_NNP 
          et_CC al_NN [_NN 30_CD ]_NN ,_, also_RB in_IN liver_NN
          transplant_NN patients_NNS ._. The_DT Swygert_NNP study_NN used_VBD 3_CD μg_NN /_NN kg_NN /_NN min_NN
          dopamine_NN and_CC found_VBD no_DT difference_NN compared_VBN to_TO placebo_NN in_IN
          terms_NNS of_IN creatinine_NN clearance_NN or_CC incidence_NN of_IN ARF_NNP (_( 4_CD %_NN in_IN
          both_DT groups_NNS )_) ._. The_DT results_NNS of_IN a_DT small_JJ level_NN V_NNP study_NN by_IN
          Palmieri_NNP 
          et_CC al_NN [_NN 26_CD ]_NN appear_VBP to_TO suggest_VB that_DT
          dopamine_NN may_MD be_VB useful_JJ in_IN shortening_VBG the_DT recovery_NN time_NN
          from_IN interleukin-_NN 2_CD -_: induced_VBN ARF_NNP ._. Apart_RB from_IN these_DT two_CD
          studies_NNS ,_, the_DT remaining_VBG 17_CD [_NN 13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ,_,
          20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ,_, 25_CD ,_, 27_CD ,_, 29_CD ,_, 30_CD ,_, 31_CD ,_, 32_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ,_,
          36_CD ,_, 37_CD ,_, 39_CD ,_, 40_CD ,_, 41_CD ,_, 42_CD ]_NN ,_, collectively_RB enrolling_VBG over_IN 700_CD
          patients_NNS ,_, are_VBP all_DT negative_NN ._. Among_IN these_DT is_VBZ a_DT recent_JJ level_NN
          II_NNP study_NN by_IN Lherm_NNP 
          et_CC al_NN [_NN 14_CD ]_NN in_IN which_WDT dopamine_NN
          infusion_NN failed_VBD to_TO improve_VB renal_JJ function_NN in_IN patients_NNS
          with_IN sepsis_NN except_IN for_IN transiently_RB increasing_VBG creatinine_NN
          clearance_NN in_IN patients_NNS without_IN shock_NN ._.
        
        
          Treatment_NNP of_IN established_VBN ATN_NNP
          Of_IN the_DT three_CD trials_NNS evaluating_VBG the_DT use_NN of_IN diuretics_NNS in_IN
          the_DT treatment_NN of_IN ATN_NNP ,_, two_CD fulfilled_VBN outcome_NN criteria_NNS ._.
          Both_DT studies_NNS evaluated_VBD the_DT effects_NNS of_IN treatment_NN on_IN
          mortality_NN and_CC the_DT need_NN for_IN dialysis_NN ._. In_IN the_DT first_JJ ,_,
          Kleinknecht_NNP 
          et_CC al_NN [_NN 11_CD ]_NN randomized_JJ 66_CD patients_NNS
          to_TO receive_VB furosemide_NN or_CC placebo_NN ._. Although_IN ,_, the_DT
          furosemide_NN group_NN did_VBD experience_NN improved_VBD urine_NN output_NN ,_,
          there_EX were_VBD no_DT significant_JJ differences_NNS between_IN the_DT two_CD
          groups_NNS in_IN terms_NNS of_IN renal_JJ recovery_NN ,_, days_NNS on_IN dialysis_NN or_CC
          mortality_NN ._. A_DT second_JJ study_NN by_IN Brown_NNP 
          et_CC al_NN [_NN 12_CD ]_NN had_VBD similar_JJ results_NNS ._. In_IN
          this_DT study_NN ,_, 58_CD patients_NNS were_VBD given_VBN a_DT single_JJ dose_NN of_IN
          furosemide_NN (_( 1_CD g_SYM )_) and_CC then_RB randomized_JJ either_CC to_TO receive_VB or_CC
          not_RB receive_VB continued_VBD diuretic_JJ therapy_NN ;_: again_RB ,_, there_EX were_VBD
          no_DT differences_NNS between_IN the_DT two_CD groups_NNS in_IN terms_NNS of_IN need_NN
          for_IN dialysis_NN or_CC survival_NN ._. Unfortunately_RB ,_, even_RB the_DT two_CD
          studies_NNS together_RB lack_VBP sufficient_JJ power_NN to_TO entirely_RB rule_VB
          out_RP the_DT possibility_NN that_IN diuretics_NNS have_VBP a_DT beneficial_JJ
          effect_NN on_IN survival_NN ._. Nonetheless_RB ,_, the_DT available_JJ literature_NN
          to_TO date_NN does_VBZ not_RB support_VB a_DT survival_NN benefit_NN for_IN this_DT
          therapy_NN ._.
        
      
      
        Discussion_NNP
        
          Diuretics_NNP and_CC ATN_NNP
          Experimentally_NNP ,_, the_DT effectiveness_NN of_IN diuretics_NNS in_IN the_DT
          prevention_NN of_IN ischemic_JJ ATN_NNP appears_VBZ to_TO be_VB related_VBN to_TO
          timing_NN ._. While_IN no_DT data_NNS exist_VBP in_IN humans_NNS ,_, several_JJ lines_NNS of_IN
          evidence_NN from_IN animal_NN experiments_NNS suggest_VBP that_WDT
          interventions_NNS such_JJ as_IN diuretics_NNS may_MD be_VB useful_JJ if_IN given_VBN
          within_IN minutes_NNS (_( or_CC perhaps_RB the_DT first_JJ few_JJ hours_NNS )_) following_VBG
          a_DT renal_JJ insult_NN [_NN 1_CD ]_NN ._. Once_RB this_DT time_NN limit_NN has_VBZ passed_VBN ,_, the_DT
          intervention_NN will_MD be_VB ineffective_JJ ._. This_DT is_VBZ because_IN the_DT
          unifying_JJ principle_NN is_VBZ cytoprotection_NN of_IN the_DT renal_JJ tubular_JJ
          cells_NNS which_WDT ,_, if_IN lethally_RB injured_VBN ,_, may_MD only_RB be_VB `_`` rescued_VBD '_''
          for_IN a_DT short_JJ time_NN ._. The_DT injury_NN to_TO the_DT renal_JJ tubular_JJ cells_NNS
          has_VBZ been_VBN attributed_VBN to_TO four_CD major_JJ factors_NNS :_: renal_JJ
          vasoconstriction_NN ,_, reduction_NN of_IN glomerular_NN capillary_JJ
          permeability_NN ,_, tubular_JJ obstruction_NN and_CC transepithelial_NN
          back-leak_JJ of_IN filtrate_NN [_NN 45_CD ]_NN ._. In_IN theory_NN ,_, loop_NN diuretics_NNS
          may_MD be_VB useful_JJ in_IN combating_VBG each_DT of_IN these_DT factors_NNS ._. These_DT
          agents_NNS decrease_VBP the_DT metabolic_JJ demand_NN of_IN the_DT renal_JJ tubular_JJ
          cell_NN ,_, reducing_VBG its_PRP$ oxygen_NN requirement_NN and_CC hence_RB
          increasing_VBG its_PRP$ resistance_NN to_TO ischemia_NN [_NN 46_CD ]_NN and_CC perhaps_RB
          to_TO other_JJ toxic_JJ insults_NNS as_RB well_RB ._. A_DT greater_JJR urine_NN flow_NN may_MD
          also_RB reduce_VB the_DT incidence_NN of_IN tubular_JJ obstruction_NN and_CC the_DT
          higher_JJR hydraulic_JJ pressures_NNS may_MD reduce_VB the_DT back-leak_JJ of_IN
          filtrate_NN [_NN 47_CD ]_NN ._. In_IN the_DT latter_JJ case_NN ,_, fluid_JJ resuscitation_NN
          alone_RB may_MD produce_VB much_JJ of_IN the_DT same_JJ effect_NN [_NN 7_CD ]_NN ._.
          In_IN practical_JJ terms_NNS these_DT data_NNS from_IN animal_NN studies_NNS
          offer_VBP little_JJ to_TO guide_VB practice_NN in_IN the_DT care_NN of_IN patients_NNS ,_,
          though_IN they_PRP provide_VBP great_JJ insight_NN into_IN the_DT various_JJ
          mechanisms_NNS of_IN ATN_NNP ._. This_DT is_VBZ because_IN it_PRP is_VBZ not_RB usually_RB
          possible_JJ to_TO anticipate_VB the_DT renal_JJ injury_NN and_CC act_NN within_IN
          the_DT time_NN required_VBN to_TO have_VB an_DT effect_NN ._. However_RB ,_, there_EX are_VBP
          notable_JJ exceptions_NNS ,_, such_JJ as_IN aortic_JJ cross-clamping_JJ in_IN
          aneurysm_NN repair_NN ._. The_DT use_NN of_IN loop_NN diuretics_NNS has_VBZ become_VBN
          routine_JJ for_IN this_DT indication_NN in_IN many_JJ institutions_NNS ._.
          Nonetheless_RB there_EX appears_VBZ to_TO be_VB no_DT evidence_NN in_IN support_NN of_IN
          this_DT approach_NN ._.
          Additionally_RB ,_, there_EX are_VBP some_DT situations_NNS in_IN which_WDT the_DT
          renal_JJ injury_NN is_VBZ subacute_NN or_CC mild_JJ and_CC sustained_VBN ._. Such_JJ is_VBZ
          often_RB the_DT case_NN in_IN conditions_NNS such_JJ as_IN rhabdomyolysis_NNS ,_,
          drug-induced_JJ renal_JJ injury_NN ,_, hepatorenal_NN syndrome_NN ,_, and_CC ARF_NNP
          associated_VBN with_IN cardiopulmonary_JJ bypass_NN circulation_NN in_IN
          cardiac_JJ surgery_NN (_( especially_RB in_IN patients_NNS with_IN
          pre-operative_JJ renal_JJ impairment_NN [_NN 48_CD ]_NN )_) ._. In_IN these_DT
          conditions_NNS it_PRP is_VBZ often_RB possible_JJ to_TO act_VB in_IN an_DT attempt_NN to_TO
          prevent_VB or_CC reduce_VB the_DT renal_JJ injury_NN as_IN it_PRP evolves_NNS ._.
          Although_IN the_DT specifics_NNS of_IN renal_JJ injury_NN vary_VBP somewhat_RB
          between_IN these_DT forms_NNS of_IN `_`` subacute_NN '_'' renal_JJ failure_NN ,_, all_DT are_VBP
          exacerbated_VBN by_IN hypovolemia_NN and_CC ,_, therefore_RB ,_, any_DT
          consideration_NN of_IN the_DT use_NN of_IN loop_NN diuretics_NNS must_MD include_VB a_DT
          provision_NN for_IN adequate_JJ volume_NN replacement_NN ._. This_DT
          requirement_NN makes_VBZ it_PRP difficult_JJ to_TO separate_VB the_DT effects_NNS of_IN
          diuretics_NNS from_IN the_DT effects_NNS of_IN the_DT increased_VBN fluid_JJ given_VBN
          to_TO prevent_VB diuretic-induced_JJ hypovolemia_NN ._. Dramatic_NNP
          evidence_NN exists_VBZ from_IN a_DT case-controlled_JJ study_NN to_TO support_VB
          the_DT use_NN of_IN (_( `_`` early_JJ and_CC aggressive_JJ '_POS )_) hydration_NN along_IN with_IN
          forced_VBN alkaline_NN /_NN osmotic_JJ diuresis_NNS (_( mannitol_NN )_) for_IN the_DT
          treatment_NN of_IN ATN_NNP secondary_JJ to_TO traumatic_JJ rhabdomyolysis_NNS [_NN
          7_CD ]_NN ._. In_IN this_DT study_NN ,_, delayed_VBN treatment_NN in_IN a_DT series_NN of_IN seven_CD
          patients_NNS was_VBD associated_VBN with_IN a_DT 100_CD %_NN incidence_NN of_IN ARF_NNP ,_,
          while_IN in_IN another_DT seven_CD patients_NNS prompt_VB treatment_NN was_VBD 100_CD %_NN
          successful_JJ in_IN avoiding_VBG this_DT complication_NN even_RB though_IN
          renal_JJ injury_NN had_VBD already_RB begun_VBN ._. Unlike_IN loop_NN diuretics_NNS ,_,
          mannitol_NN functions_NNS as_IN an_DT intravascular_NN volume_NN expander_NN ,_,
          at_IN least_JJS initially_RB ,_, and_CC may_MD also_RB function_VB as_IN a_DT
          free-radical_JJ scavenger_NN ._. None_NN of_IN these_DT patients_NNS received_VBD
          loop_NN diuretics_NNS and_CC ,_, indeed_RB ,_, the_DT authors_NNS have_VBP argued_VBN that_DT
          hydration_NN alone_RB may_MD have_VB been_VBN sufficient_JJ to_TO produce_VB many_JJ
          of_IN salutary_JJ effects_NNS of_IN the_DT osmotic_JJ diuresis_NNS [_NN 7_CD ]_NN ._.
          Once_RB ATN_NNP is_VBZ established_VBN there_EX are_VBP no_DT therapies_NNS that_WDT
          have_VBP been_VBN proven_VBN to_TO reverse_VB it_PRP ._. The_DT most_JJS a_DT clinician_NN can_MD
          do_VB is_VBZ to_TO manage_VB the_DT complications_NNS of_IN ARF_NNP and_CC limit_VB
          further_JJ renal_JJ insult_NN so_RB as_IN to_TO assure_VB the_DT best_JJS chance_NN of_IN
          renal_JJ recovery_NN ._. Diuretics_NNP can_MD be_VB both_DT useful_JJ and_CC harmful_JJ
          in_IN this_DT regard_NN ._. The_DT harm_NN comes_VBZ from_IN reducing_VBG the_DT
          circulating_VBG volume_NN too_RB much_JJ and_CC adding_VBG a_DT prerenal_NN insult_NN
          on_IN top_NN of_IN the_DT established_VBN ATN_NNP ._. The_DT recovering_VBG kidney_NN may_MD
          be_VB even_RB more_RBR susceptible_JJ to_TO this_DT `_`` second_RB hit_NN '_POS and_CC may_MD be_VB
          profoundly_RB injured_VBN by_IN a_DT relatively_RB mild_JJ decrease_NN in_IN
          perfusion_NN ,_, especially_RB with_IN the_DT pre-existing_JJ renal_JJ
          disease_NN ._. Clinicians_NNP may_MD inadvertently_RB produce_VB this_DT injury_NN
          if_IN diuretics_NNS are_VBP dosed_JJ according_VBG to_TO the_DT amount_NN of_IN
          peripheral_JJ edema_NN or_CC body_NN weight_NN without_IN consideration_NN of_IN
          intravascular_NN volume_NN ._. This_DT may_MD be_VB of_IN particular_JJ concern_NN
          in_IN many_JJ critically_RB ill_JJ patients_NNS with_IN hypoalbuminemia_NN ._.
          These_DT patients_NNS may_MD have_VB coexisting_VBG total_JJ body_NN volume_NN
          overload_NN and_CC intravascular_NN volume_NN depletion_NN ._.
          However_RB ,_, if_IN volume_NN status_NN is_VBZ monitored_VBN closely_RB ,_,
          diuretics_NNS can_MD be_VB useful_JJ in_IN the_DT conversion_NN to_TO nonoliguria_NN ._.
          This_DT goal_NN may_MD be_VB reasonable_JJ in_IN certain_JJ situations_NNS and_CC
          patients_NNS are_VBP clearly_RB easier_JJR to_TO manage_VB without_IN volume_NN
          overload_NN and_CC electrolyte_NN imbalances_NNS ._. In_IN this_DT regard_NN ,_, loop_NN
          diuretics_NNS appear_VBP to_TO be_VB more_RBR effective_JJ and_CC less_RBR toxic_JJ when_WRB
          given_VBN as_IN a_DT continuous_JJ infusion_NN rather_RB than_IN as_IN a_DT bolus_JJ ._. In_IN
          a_DT randomized_JJ ,_, crossover_NN trial_NN ,_, Rudy_NNP 
          et_CC al_NN [_NN 49_CD ]_NN evaluated_VBD the_DT
          effectiveness_NN of_IN continuous_JJ infusion_NN 
          vs_NNS bolus_JJ dosing_VBG of_IN bumetanide_NN ._.
          Continuous_NNP infusion_NN produced_VBD 48_CD mmol_NN more_RBR net_JJ sodium_NN
          excretion_NN (_( 95_CD %_NN CI_NNP 16_CD -_: 80_CD mmol_NN ,_, 
          P_NN =_SYM 0_CD ._. 01_CD )_) ,_, and_CC less_JJR toxicity_NN ._. It_PRP is_VBZ
          also_RB important_JJ to_TO note_VB that_IN large_JJ bolus_JJ doses_NNS of_IN loop_NN
          diuretics_NNS may_MD cause_VB transient_JJ renal_JJ vasoconstriction_NN ._.
          Despite_IN these_DT potentially_RB useful_JJ effects_NNS of_IN diuretic_JJ
          therapy_NN ,_, there_EX is_VBZ no_DT evidence_NN that_IN converting_VBG oliguria_NN
          into_IN nonoliguria_NN is_VBZ effective_JJ in_IN reducing_VBG mortality_NN or_CC
          the_DT need_NN for_IN dialysis_NN ._. As_IN detailed_JJ above_IN ,_, this_DT question_NN
          has_VBZ now_RB been_VBN evaluated_VBN in_IN two_CD randomized_JJ trials_NNS [_NN 11_CD ,_,
          12_CD ]_NN ._.
        
        
          Medullary_NNP ischemia_NN ,_, renal_JJ blood_NN flow_NN and_CC
          dopamine_NN
          In_IN general_JJ ,_, ATN_NNP occurs_VBZ more_RBR commonly_RB in_IN patients_NNS with_IN
          certain_JJ types_NNS of_IN underlying_VBG physiologic_JJ states_NNS or_CC
          diseases_NNS (_( elderly_JJ ,_, relative_JJ hypovolemia_NN ,_, diabetes_NN ,_,
          underlying_VBG kidney_NN disease_NN ,_, heart_NN disease_NN ,_, hepatic_JJ
          cirrhosis_NNS ,_, certain_JJ autoimmune_JJ diseases_NNS and_CC malignancies_NNS )_)
          as_RB well_RB as_IN in_IN certain_JJ clinical_JJ settings_NNS (_( sepsis_NN ,_, surgery_NN ,_,
          trauma_NN ,_, drug-induced_JJ )_) ._. Indeed_RB ,_, one_CD of_IN the_DT most_RBS commonly_RB
          anticipated_VBN etiologies_NNS of_IN ATN_NNP is_VBZ the_DT use_NN of_IN iv_NN contrast_NN
          agents_NNS for_IN imaging_NN studies_NNS [_NN 43_CD ]_NN ._. Although_IN the_DT
          pathogenesis_NNS of_IN renal_JJ injury_NN secondary_JJ to_TO radiocontrast_NN
          agents_NNS is_VBZ not_RB entirely_RB understood_VBN ,_, it_PRP appears_VBZ to_TO be_VB due_JJ
          to_TO medullary_JJ ischemia_NN [_NN 3_CD ,_, 50_CD ]_NN ._. For_IN some_DT time_NN ,_, it_PRP has_VBZ
          been_VBN postulated_JJ that_IN this_DT ischemic_JJ injury_NN occurs_VBZ on_IN the_DT
          basis_NN of_IN decreased_VBD renal_JJ blood_NN flow_NN secondary_JJ to_TO renal_JJ
          vasoconstriction_NN ._. It_PRP is_VBZ therefore_RB surprising_JJ that_IN studies_NNS
          have_VBP now_RB shown_VBN that_IN renal_JJ blood_NN flow_NN actually_RB increases_VBZ
          with_IN radiocontrast_NN [_NN 24_CD ]_NN ._. This_DT has_VBZ led_VBN some_DT investigators_NNS
          to_TO hypothesize_NN that_IN medullary_JJ ischemia_NN is_VBZ a_DT demand-side_JJ
          phenomenon_NN ._. In_IN other_JJ words_NNS ,_, the_DT ionic_JJ load_NN leads_VBZ to_TO
          medullary_JJ ischemia_NN because_IN the_DT medullary_JJ cellular_JJ oxygen_NN
          demand_NN becomes_VBZ greater_JJR than_IN the_DT supply_NN [_NN 51_CD ,_, 52_CD ]_NN ._. This_DT
          aspect_NN of_IN renal_JJ physiology_NN also_RB has_VBZ implications_NNS for_IN the_DT
          use_NN of_IN agents_NNS like_IN dopamine_NN ._.
          Like_IN loop_NN diuretics_NNS ,_, dopamine_NN is_VBZ frequently_RB used_VBN by_IN
          clinicians_NNS to_TO increase_VB urine_NN output_NN in_IN ARF_NNP in_IN the_DT hope_NN
          that_IN such_JJ a_DT maneuver_NN might_MD attenuate_NN renal_JJ injury_NN or_CC
          improve_VB survival_NN ._. Much_JJ of_IN the_DT enthusiasm_NN for_IN this_DT agent_NN
          comes_VBZ from_IN the_DT belief_NN that_IN dopamine_NN increases_NNS renal_JJ blood_NN
          flow_NN and_CC that_IN such_JJ an_DT outcome_NN is_VBZ in_IN fact_NN desirable_JJ ._.
          Additionally_RB ,_, clinicians_NNS often_RB interpret_VBP an_DT increase_NN in_IN
          urine_NN output_NN as_IN proof_NN that_IN these_DT two_CD assumptions_NNS are_VBP
          valid_JJ ._. Indeed_RB ,_, dopamine_NN may_MD increase_VB urine_NN output_NN through_IN
          four_CD separate_JJ mechanisms_NNS ._. Dopamine_NNP stimulates_NNS both_DT
          dopaminergic_JJ and_CC adrenergic_JJ (_( both_DT alpha_NN and_CC beta_NN )_)
          receptors_NNS ._. As_IN such_JJ ,_, dopamine_NN may_MD affect_VB renal_JJ blood_NN flow_NN
          by_IN direct_JJ vasodilatation_NN (_( dopamine_NN receptors_NNS )_) ,_, by_IN
          increasing_VBG cardiac_JJ output_NN (_( beta_NN receptors_NNS )_) or_CC by_IN
          increasing_VBG perfusion_NN pressure_NN (_( alpha_NN receptors_NNS )_) ._. At_IN lower_JJR
          doses_NNS ,_, particularly_RB less_JJR than_IN 2_CD μg_NN /_NN kg_NN /_NN min_NN ,_, the_DT
          dopaminergic_JJ effects_NNS tend_VBP to_TO predominate_NN ,_, although_IN wide_JJ
          variability_NN appears_VBZ to_TO exist_VB across_IN patients_NNS and_CC clinical_JJ
          conditions_NNS ._. In_IN the_DT appropriate_JJ clinical_JJ setting_NN ,_, any_DT of_IN
          these_DT mechanisms_NNS might_MD increase_VB effective_JJ renal_JJ plasma_NN
          flow_NN and_CC thus_RB increase_VB urine_NN output_NN ._. Under_IN such_JJ
          conditions_NNS ,_, the_DT increase_NN in_IN urine_NN output_NN might_MD well_RB be_VB
          indicative_JJ of_IN improved_VBN renal_JJ function_NN ._. However_RB ,_, dopamine_NN
          may_MD increase_VB urine_NN output_NN by_IN yet_RB a_DT fourth_JJ mechanism_NN ,_, that_IN
          of_IN inhibition_NN of_IN sodium-potassium_JJ ATPase_NNP at_IN the_DT tubular_JJ
          epithelial_NN cell_NN level_NN [_NN 53_CD ]_NN ._. The_DT effect_NN of_IN this_DT final_JJ
          mechanism_NN is_VBZ to_TO increase_VB sodium_NN excretion_NN and_CC thereby_RB
          diuresis_NNS ._. Thus_RB ,_, apart_RB from_IN its_PRP$ direct_JJ and_CC indirect_JJ
          effects_NNS on_IN the_DT renal_JJ vasculature_NN ,_, dopamine_NN increases_NNS
          urine_NN output_NN because_IN it_PRP is_VBZ a_DT diuretic_JJ ._.
          The_DT natriuretic_JJ /_NN diuretic_JJ effects_NNS of_IN dopamine_NN are_VBP of_IN
          importance_NN not_RB only_RB because_IN they_PRP may_MD lull_NN clinicians_NNS into_IN
          believing_VBG that_IN they_PRP are_VBP improving_VBG renal_JJ function_NN when_WRB
          they_PRP observe_VBP an_DT increase_NN in_IN urine_NN output_NN with_IN the_DT drug_NN ,_,
          but_CC also_RB because_IN this_DT increase_NN in_IN urine_NN output_NN may_MD come_VB
          with_IN unexpected_JJ effects_NNS ._. Most_JJS `_`` enthusiasts_NNS '_'' use_NN so-called_JJ
          '_POS renal-dose_JJ dopamine_NN '_'' in_IN the_DT belief_NN that_IN they_PRP can_MD improve_VB
          renal_JJ blood_NN flow_NN and_CC that_IN this_DT will_MD restore_VB oxygen_NN
          delivery_NN to_TO portions_NNS of_IN the_DT kidney_NN that_WDT are_VBP dysoxic_JJ ._.
          Unfortunately_RB ,_, as_RB already_RB discussed_VBN ,_, the_DT problem_NN may_MD not_RB
          be_VB remedied_VBN simply_RB by_IN increasing_VBG total_JJ renal_JJ blood_NN flow_NN ._.
          This_DT is_VBZ because_IN the_DT area_NN of_IN the_DT kidney_NN that_WDT is_VBZ most_JJS at_IN
          risk_NN from_IN ischemia_NN is_VBZ the_DT very_JJ area_NN least_JJS likely_JJ to_TO
          benefit_VB from_IN dopamine_NN infusion_NN ._. This_DT area_NN is_VBZ the_DT outer_JJ
          medulla_NN ._. Normally_RB ,_, outer_JJ medullary_JJ cells_NNS live_VBP on_IN the_DT edge_NN
          of_IN dysoxia_NN ._. Oxygen_NNP diffuses_NNS from_IN the_DT descending_VBG to_TO
          ascending_VBG vasa_NN recta_NN within_IN the_DT vascular_NN bundles_NNS limiting_VBG
          oxygen_NN delivery_NN to_TO the_DT renal_JJ medulla_NN [_NN 52_CD ]_NN ._. In_IN addition_NN
          the_DT medulla_NN suffers_VBZ from_IN unusually_RB high_JJ oxygen_NN demand_NN
          related_VBN to_TO tubular_JJ transport_NN activity_NN (_( medullary_JJ oxygen_NN
          extraction_NN approaches_NNS 90_CD %_NN [_NN 54_CD ]_NN ._. Thus_RB ,_, the_DT renal_JJ medulla_NN
          is_VBZ constantly_RB on_IN the_DT brink_NN of_IN dysoxia_NN owing_VBG to_TO high_JJ
          demand_NN and_CC low_JJ delivery_NN of_IN oxygen_NN ._.
          Given_VBN these_DT considerations_NNS ,_, it_PRP is_VBZ certainly_RB
          understandable_JJ for_IN clinicians_NNS to_TO desire_NN to_TO increase_VB renal_JJ
          blood_NN flow_NN in_IN the_DT hope_NN of_IN improving_VBG medullary_JJ oxygen_NN
          delivery_NN ._. However_RB ,_, Heyman_NNP 
          et_CC al_NN have_VBP recently_RB demonstrated_VBN
          that_IN although_IN dopamine_NN increased_VBD outer_JJ medullary_JJ blood_NN
          flow_NN in_IN the_DT hypovolemic_JJ rat_NN ,_, it_PRP failed_VBD to_TO improve_VB outer_JJ
          medullary_JJ dysoxia_NN [_NN 55_CD ]_NN ._. In_IN fact_NN ,_, analogous_JJ to_TO the_DT
          situation_NN with_IN radio-contrast_JJ ,_, the_DT increase_NN in_IN solute_NN
          delivery_NN to_TO the_DT distal_NN tubular_JJ cells_NNS produced_VBN by_IN the_DT
          natriuretic_JJ effects_NNS of_IN dopamine_NN (_( via_IN inhibition_NN of_IN
          proximal_NN tubular_JJ reabsorption_NN )_) might_MD actually_RB increase_VB
          their_PRP$ oxygen_NN consumption_NN and_CC therefore_RB increase_VB rather_RB
          than_IN decrease_VB the_DT risk_NN of_IN ischemia_NN [_NN 56_CD ]_NN ._.
          With_IN these_DT `_`` myths_NNS '_'' of_IN experimental_JJ evidence_NN dispelled_VBD ,_,
          or_CC at_IN least_JJS severely_RB questioned_VBD ,_, it_PRP is_VBZ not_RB surprising_JJ
          that_IN clinical_JJ trials_NNS have_VBP failed_VBN to_TO demonstrate_VB a_DT
          beneficial_JJ effect_NN from_IN dopamine_NN infusion_NN in_IN the_DT setting_NN
          of_IN treatment_NN or_CC prevention_NN of_IN ATN_NNP [_NN 57_CD ,_, 58_CD ]_NN ._. Data_NNS of_IN this_DT
          sort_NN also_RB call_NN into_IN question_NN the_DT appropriateness_NN of_IN
          increasing_VBG urine_NN output_NN in_IN the_DT first_JJ place_NN ._. As_IN we_PRP have_VBP
          seen_VBN with_IN other_JJ types_NNS of_IN diuretics_NNS ,_, converting_VBG oliguric_JJ
          to_TO nonoliguric_JJ renal_JJ failure_NN may_MD provide_VB certain_JJ
          management_NN advantages_NNS ,_, but_CC does_VBZ not_RB affect_VB overall_JJ renal_JJ
          recovery_NN or_CC outcome_NN ._. Accordingly_RB ,_, on_IN the_DT basis_NN of_IN
          existing_VBG evidence_NN ,_, the_DT use_NN of_IN dopamine_NN to_TO improve_VB renal_JJ
          function_NN cannot_NN be_VB recommended_VBN ._. This_DT is_VBZ not_RB to_TO say_VB that_DT
          dopamine_NN is_VBZ not_RB a_DT useful_JJ drug_NN ._. Indeed_RB ,_, dopamine_NN 's_POS
          multiple_JJ effects_NNS (_( even_RB at_IN low_JJ doses_NNS )_) make_VB it_PRP the_DT perfect_JJ
          pressor_NN /_NN inotropic_JJ agent_NN when_WRB such_JJ a_DT combination_NN is_VBZ
          warranted_VBN ._. It_PRP is_VBZ a_DT common_JJ clinical_JJ scenario_NN in_IN which_WDT a_DT
          patient_NN is_VBZ both_DT modestly_RB hypotensive_JJ /_NN vasodilated_JJ and_CC has_VBZ
          a_DT degree_NN of_IN cardiac_JJ dysfunction_NN ._. Such_JJ a_DT patient_NN may_MD well_RB
          benefit_VB from_IN the_DT combined_VBN inotropic_JJ ,_, vasopressor_NN ,_, renal_JJ
          vasodilator_NN and_CC diuretic_JJ effects_NNS of_IN this_DT drug_NN ._. However_RB ,_,
          as_IN always_RB ,_, when_WRB safer_JJR or_CC less_RBR invasive_JJ alternatives_NNS are_VBP
          available_JJ ,_, they_PRP should_MD be_VB used_VBN first_JJ ._. For_IN example_NN ,_, loop_NN
          diuretics_NNS are_VBP much_RB more_RBR effective_JJ diuretics_NNS than_IN dopamine_NN
          and_CC are_VBP much_RB safer_JJR ._. Similarly_RB ,_, dobutamine_NN would_MD be_VB a_DT
          better_JJR alternative_NN for_IN the_DT patient_NN who_WP primarily_RB requires_VBZ
          an_DT inotrope_NN ,_, and_CC norepinephrine_NN would_MD be_VB a_DT better_JJR choice_NN
          for_IN a_DT vasodilated_JJ ,_, hyperdynamic_JJ patient_NN ._.
          Certainly_RB ,_, dopamine_NN has_VBZ a_DT number_NN of_IN potential_JJ
          disadvantages_NNS ._. In_IN a_DT recent_JJ study_NN ,_, Segal_NNP 
          et_CC al_NN demonstrated_VBN that_IN low-dose_JJ
          dopamine_NN caused_VBN earlier_JJR onset_NN of_IN gut_NN ischemia_NN [_NN 59_CD ]_NN ._. Even_RB
          at_IN low_JJ doses_NNS ,_, dopamine_NN may_MD increase_VB cardiac_JJ contractility_NN
          and_CC systemic_JJ resistance_NN ,_, and_CC can_MD cause_VB tissue_NN necrosis_NNS
          and_CC digital_JJ gangrene_NN [_NN 60_CD ]_NN ._. Furthermore_RB ,_, even_RB if_IN dopamine_NN
          were_VBD without_IN risk_NN ,_, its_PRP$ effects_NNS can_MD be_VB unpredictable_JJ ._. This_DT
          point_NN was_VBD stressed_VBN by_IN Flancbaum_NNP 
          et_CC al_NN ,_, who_WP demonstrated_VBD that_IN
          low-dose_JJ infusion_NN alone_RB produces_VBZ a_DT drug-dependent_JJ
          increase_NN in_IN the_DT urinary_JJ output_NN in_IN oliguric_JJ ,_, euvolemic_JJ ICU_NNP
          patients_NNS ,_, and_CC that_IN the_DT maximal_NN effect_NN is_VBZ temporally_RB
          variable_JJ [_NN 13_CD ]_NN ._. Given_VBN the_DT fact_NN that_IN the_DT renal_JJ effects_NNS of_IN
          low-dose_JJ dopamine_NN in_IN patients_NNS with_IN sepsis_NN syndrome_NN
          decrease_NN with_IN time_NN ,_, it_PRP has_VBZ been_VBN suggested_VBN that_IN there_EX is_VBZ a_DT
          desensitization_NN of_IN renal_JJ dopaminergic_JJ receptors_NNS [_NN 14_CD ]_NN ._.
          The_DT above_IN considerations_NNS argue_VBP against_IN the_DT routine_JJ use_NN of_IN
          '_POS renal-dose_JJ dopamine_NN '_'' for_IN patients_NNS with_IN renal_JJ
          insufficiency_NN ._.
        
        
          Conclusions_NNP
          The_DT use_NN of_IN diuretics_NNS in_IN the_DT management_NN of_IN ARF_NNP remains_VBZ
          controversial_JJ despite_IN several_JJ advances_NNS in_IN the_DT
          understanding_NN of_IN the_DT pathogenesis_NNS of_IN renal_JJ failure_NN and_CC
          the_DT mechanisms_NNS of_IN action_NN of_IN the_DT agents_NNS commonly_RB used_VBN to_TO
          manage_VB it_PRP ._.
          At_IN the_DT present_JJ time_NN the_DT limited_JJ observational_NN and_CC
          experimental_JJ evidence_NN available_JJ moderately_RB supports_VBZ the_DT
          following_JJ guidelines_NNS :_:
          1_LS ._. For_IN prophylaxsis_NNS against_IN radiocontrast-induced_JJ ATN_NNP ,_,
          saline_NN infusion_NN should_MD be_VB administered_VBN for_IN optimal_NN
          hydration_NN ;_: neither_DT diuretics_NNS nor_CC dopamine_NN appear_VBP
          effective_JJ and_CC may_MD be_VB harmful_JJ ._.
          2_LS ._. For_IN the_DT prevention_NN of_IN ischemic_JJ ATN_NNP ,_, although_IN animal_NN
          data_NNS suggest_VBP this_DT intervention_NN would_MD be_VB helpful_JJ ,_, there_EX
          are_VBP no_DT human_JJ data_NN to_TO support_VB the_DT use_NN of_IN diuretics_NNS ._.
          3_LS ._. The_DT use_NN of_IN '_POS renal-dose_JJ dopamine_NN '_'' has_VBZ not_RB been_VBN
          substantiated_JJ to_TO improve_VB outcome_NN in_IN human_JJ studies_NNS and_CC may_MD
          prove_VB to_TO be_VB deleterious_JJ in_IN certain_JJ clinical_JJ settings_NNS ._.
          4_LS ._. In_IN the_DT management_NN of_IN rhabdomyolysis_NNS ,_, loop_NN diuretics_NNS
          should_MD probably_RB be_VB avoided_VBN ,_, although_IN mannitol_NN may_MD be_VB
          effective_JJ on_IN the_DT basis_NN of_IN level_NN IV_NNP evidence_NN ._.
          5_LS ._. When_WRB loop_NN diuretics_NNS are_VBP used_VBN in_IN the_DT management_NN of_IN
          ARF_NNP ,_, continuous_JJ infusion_NN may_MD be_VB more_RBR efficacious_JJ than_IN
          bolus_JJ administration_NN in_IN achieving_VBG diuresis_NNS ._. However_RB ,_,
          there_EX is_VBZ no_DT evidence_NN that_IN this_DT maneuver_NN improves_VBZ survival_NN
          or_CC renal_JJ recovery_NN ._.
        
      
    
  
